Emerging role of GLP-1 receptor agonists in the treatment of obesity

QR Code

Emerging role of GLP-1 receptor agonists in the treatment of obesity

Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Neff LM
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	obesity GLP-1 exenatide liraglutide Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/c3a463ab4c97492ba35bd936794ad4f1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
par: Courtney H, et autres
Publié: (2017)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Lisa M Neff, et autres
Publié: (2010)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
par: Knop FK, et autres
Publié: (2010)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
par: Chudleigh RA, et autres
Publié: (2020)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
par: Martin AA, et autres
Publié: (2016)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
par: Bastin M, et autres
Publié: (2019)

Clinical Impact of Liraglutide as a Treatment of Obesity
par: Alruwaili H, et autres
Publié: (2021)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
par: Qiao Q, et autres
Publié: (2016)

Role and development of GLP-1 receptor agonists in the management of diabetes
par: Chee&nbsp;W Chia, et autres
Publié: (2009)

Associations of TCF7L2 rs11196218 (A/G) and GLP-1R rs761386 (C/T) Gene Polymorphisms with Obesity in Chinese Population
par: Xu T, et autres
Publié: (2021)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
par: Saunders WB, et autres
Publié: (2016)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
par: Seewoodhary J, et autres
Publié: (2010)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
par: Toomas Jagomäe, et autres
Publié: (2021)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
par: Lee SP, et autres
Publié: (2019)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
par: Stolar MW, et autres
Publié: (2013)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
par: Li Z, et autres
Publié: (2019)

Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes
par: Pan X, et autres
Publié: (2019)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
par: Orme ME, et autres
Publié: (2017)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
par: Reed J, et autres
Publié: (2021)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
par: Yanbin Dong, et autres
Publié: (2021)

Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway
par: Liu H, et autres
Publié: (2020)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
par: Cheng F, et autres
Publié: (2019)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
par: Thompson AM, et autres
Publié: (2016)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
par: Campbell RK, et autres
Publié: (2010)

A paradigm shift for the prevention and treatment of individual and global obesity
par: Slyper AH
Publié: (2018)

Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action
par: Firouzi S, et autres
Publié: (2018)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
par: Liu F, et autres
Publié: (2020)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
par: Wharton S, et autres
Publié: (2017)

The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
par: Daria A. Skuratovskaia, et autres
Publié: (2019)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
par: Gurung T, et autres
Publié: (2015)

COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment
par: Zhu X, et autres
Publié: (2020)

Obesity and brain illness: from cognitive and psychological evidences to obesity paradox
par: Monda V, et autres
Publié: (2017)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
par: Morieri ML, et autres
Publié: (2020)

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
par: Sonia A Tucci, et autres
Publié: (2010)

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publié: (2009)

Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
par: Hurt RT, et autres
Publié: (2018)

Is obesity in women protective against osteoporosis?
par: Migliaccio S, et autres
Publié: (2011)

Clinic, Anthropometric And Metabolic Changes In Adults With Class III Obesity Classified As Metabolically Healthy And Metabolically Unhealthy
par: Loureiro LM, et autres
Publié: (2019)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
par: Schuster D
Publié: (2010)